BioN­Tech and Re­gen­eron ex­pand their can­cer part­ner­ship, push­ing new Lib­tayo com­bo in­to NSCLC

Af­ter go­ing back to the ne­go­ti­at­ing ta­ble, BioN­Tech and Re­gen­eron have come away with an ex­pand­ed col­lab­o­ra­tion push­ing their ef­forts in­to lung can­cer.

The two built up­on a pre­vi­ous deal in which re­searchers eval­u­at­ed the PD-1 an­ti­body Lib­tayo in com­bi­na­tion with an ex­per­i­men­tal mR­NA can­cer vac­cine. Where­as the ear­li­er deal cen­tered around a melanoma pro­gram, Tues­day’s part­ner­ship will fo­cus on a can­di­date for NSCLC. No fi­nan­cials were dis­closed, but the two not­ed they will share de­vel­op­ment costs 50-50.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER